Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kirbee Johnston

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Pharmacy (Basel, Switzerland)|October 26, 2022
Pharmacists' Knowledge and Perceptions of FDA Approval Standards and the Breakthrough Therapy DesignationMegan C Herink, Kirbee Johnston, Kristin Breninger, et al.
Journal of the American Pharmacists Association : Japha|July 22, 2018
Pharmacists' attitudes, knowledge, utilization, and outcomes involving prescription drug monitoring programs: A brief scoping reviewKirbee Johnston, Lindsey Alley, Kevin Novak, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 16, 2019
Repository Corticotropin Versus Glucocorticoid for Nephrotic Syndrome: When Will We See the Evidence?Daniel M Hartung, Kirbee Johnston, Atul Deodhar, et al.
Pharmacoepidemiology and Drug Safety|September 17, 2020
A comparison of trends in opioid dispensing patterns between Medicaid pharmacy claims and prescription drug monitoring program dataSanae El Ibrahimi, Sara Hallvik, Kirbee Johnston, et al.
JAMA|February 13, 2019
Buprenorphine Coverage in the Medicare Part D Program for 2007 to 2018Daniel M Hartung, Kirbee Johnston, Jonah Geddes, et al.
Pharmacoepidemiology and Drug Safety|August 27, 2020
Identifying opioid dose reductions and discontinuation among patients with chronic opioid therapySara E Hallvik, Kirbee Johnston, Jonah Geddes, et al.
JAMA Network Open|January 16, 2019
Industry Payments to Physician Specialists Who Prescribe Repository CorticotropinDaniel M Hartung, Kirbee Johnston, David M Cohen, et al.
Annals of the Rheumatic Diseases|January 25, 2018
Elephant in the roomDaniel M Hartung, Kirbee Johnston, David M Cohen, et al.
JAMA Internal Medicine|September 12, 2017
Trends and Characteristics of US Medicare Spending on Repository CorticotropinDaniel M Hartung, Kirbee Johnston, Shelby Van Leuven, et al.
Journal of Substance Abuse Treatment|October 3, 2021
Characteristics and health care events of patients admitted to treatment for both heroin and methamphetamine compared to patients admitted for heroin onlySanae El Ibrahimi, Sara Hallvik, Kirbee Johnston, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Pharmacy (Basel, Switzerland)|October 26, 2022
Pharmacists' Knowledge and Perceptions of FDA Approval Standards and the Breakthrough Therapy DesignationMegan C Herink, Kirbee Johnston, Kristin Breninger, et al.
Journal of the American Pharmacists Association : Japha|July 22, 2018
Pharmacists' attitudes, knowledge, utilization, and outcomes involving prescription drug monitoring programs: A brief scoping reviewKirbee Johnston, Lindsey Alley, Kevin Novak, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 16, 2019
Repository Corticotropin Versus Glucocorticoid for Nephrotic Syndrome: When Will We See the Evidence?Daniel M Hartung, Kirbee Johnston, Atul Deodhar, et al.
Pharmacoepidemiology and Drug Safety|September 17, 2020
A comparison of trends in opioid dispensing patterns between Medicaid pharmacy claims and prescription drug monitoring program dataSanae El Ibrahimi, Sara Hallvik, Kirbee Johnston, et al.
JAMA|February 13, 2019
Buprenorphine Coverage in the Medicare Part D Program for 2007 to 2018Daniel M Hartung, Kirbee Johnston, Jonah Geddes, et al.
Pharmacoepidemiology and Drug Safety|August 27, 2020
Identifying opioid dose reductions and discontinuation among patients with chronic opioid therapySara E Hallvik, Kirbee Johnston, Jonah Geddes, et al.
JAMA Network Open|January 16, 2019
Industry Payments to Physician Specialists Who Prescribe Repository CorticotropinDaniel M Hartung, Kirbee Johnston, David M Cohen, et al.
Annals of the Rheumatic Diseases|January 25, 2018
Elephant in the roomDaniel M Hartung, Kirbee Johnston, David M Cohen, et al.
JAMA Internal Medicine|September 12, 2017
Trends and Characteristics of US Medicare Spending on Repository CorticotropinDaniel M Hartung, Kirbee Johnston, Shelby Van Leuven, et al.
Journal of Substance Abuse Treatment|October 3, 2021
Characteristics and health care events of patients admitted to treatment for both heroin and methamphetamine compared to patients admitted for heroin onlySanae El Ibrahimi, Sara Hallvik, Kirbee Johnston, et al.
Pageof 2